These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23242941)

  • 1. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.
    Pakosch D; Papadimas D; Munding J; Kawa D; Kriwalsky MS
    Oral Maxillofac Surg; 2013 Dec; 17(4):303-6. PubMed ID: 23242941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteonecrosis of the jaws and bevacizumab therapy: a case report.
    Brunamonti Binello P; Bandelloni R; Labanca M; Buffoli B; Rezzani R; Rodella LF
    Int J Immunopathol Pharmacol; 2012; 25(3):789-91. PubMed ID: 23058032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S; Lumachi F; Stellini E; Favero L
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage 0 osteonecrosis of the jaw in a patient on denosumab.
    Aghaloo TL; Dry SM; Mallya S; Tetradis S
    J Oral Maxillofac Surg; 2014 Apr; 72(4):702-16. PubMed ID: 24397946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the mandible associated with bevacizumab therapy.
    Santos-Silva AR; Belizário Rosa GA; Castro Júnior Gd; Dias RB; Prado Ribeiro AC; Brandão TB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):e32-6. PubMed ID: 23567260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
    Francini F; Pascucci A; Francini E; Miano ST; Bargagli G; Ruggiero G; Petrioli R
    J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
    Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
    J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
    Fusco V; Porta C; Saia G; Paglino C; Bettini G; Scoletta M; Bonacina R; Vescovi P; Merigo E; Lo Re G; Guglielmini P; Di Fede O; Campisi G; Bedogni A
    Clin Genitourin Cancer; 2015 Aug; 13(4):287-294. PubMed ID: 25586958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
    Antonuzzo L; Lunghi A; Petreni P; Brugia M; Laffi A; Giommoni E; Mela MM; Mazzoni F; Balestri V; Costanzo FD
    Curr Med Chem; 2017; 24(28):3068-3076. PubMed ID: 28494743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Osteonecrosis of the jaw developing during bisphosphonate treatment].
    Udvardy E; Redl P; Márton I
    Magy Onkol; 2008 Mar; 52(1):81-7. PubMed ID: 18403302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
    [No Abstract]   [Full Text] [Related]  

  • 14. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
    Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
    Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.
    Bettini G; Blandamura S; Saia G; Bedogni A
    BMJ Case Rep; 2012 Oct; 2012():. PubMed ID: 23093510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of osteonecrosis of the jaw during treatment by bevacizumab for sigmoid colon cancer].
    Sato M; Ono F; Yamamura A; Onochi S
    Nihon Shokakibyo Gakkai Zasshi; 2013 Apr; 110(4):655-9. PubMed ID: 23558129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab-associated osteonecrosis of the jaw--a case report.
    Vyas S; Hameed S; Murugaraj V
    Dent Update; 2014 Jun; 41(5):449-50. PubMed ID: 25073227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review.
    Crépin S; Laroche ML; Sarry B; Merle L
    Eur J Clin Pharmacol; 2010 Jun; 66(6):547-54. PubMed ID: 20437036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
    Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
    Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.